Efalizumab: profile and news

XOMA Announces March 9 Discussion of 2005 Financial Results 06 Mar 2006
...diseases. XOMA has a royalty interest in RAPTIVA® (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. ... - Market Wire (press release)

XOMA Announces Successful Exchange Offer With A Tender of 100% of ... Feb 9, 2006
XOMA has a royalty interest in RAPTIVA(R) (efalizumab), a monoclonal antibody product marketed to treat moderate-to-severe plaque psoriasis. ... - Genetic Engineering News,

Flat sales in Q4 for Serono; no word on buyer Feb 6, 2006
Raptiva (efalizumab), Serono's new drug for psoriasis, helped offset as sales more than doubled to $12 million in the quarter, but the fall-off in sales ... - Pharma Times (subscription),

Inflammatory Diseases - Both Chronic Diseases, Such as Rheumatoid ... Feb 1, 2006
...competition from drugs that offer alternative approaches to the treatment of inflammatory disease, including the T-cell modulators efalizumab and alefacept and ... - Genetic Engineering News,

Emory awarded grant for diabetes research Feb 2, 2006
One project will analyze the effectiveness and safety of the drug Efalizumab, which is part of the drug regimen for islet transplant patients. ... - The Emory Wheel

Other information

Indication
For treatment of psoriasis

Pharmacology
Lymphocyte activation and trafficking to skin play a role in the pathophysiology of chronic plaque psoriasis. In psoriatic skin, ICAM-1 cell surface expression is upregulated on endothelium and keratinocytes. Raptiva inhibits the binding of LFA-1 to the intercellular adhesion molecule-1 (ICAM-1), thereby inhibiting the adhesion of leukocytes to other cell types.

Mechanism Of Action
Raptiva binds to CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed on all leukocytes. As a result Raptiva decreases cell surface expression of CD11a.

Drug Category
Immunomodulatory Agents; Immunosupressants

Brand Names/Synonyms
Raptiva; hu1124; antiCD11 alpha; anti alphaL integrin; Raptiva (Genentech Inc)

Dosage Forms
Not Available

Absorption
Not Available

Interactions
Not Available

Chemical IUPAC Name
Humanized anti-CD11a antibody

Chemical Formula
Not Available

Half Life
Not Available

Drug Type
Approved Drug

# Accession No
BIOD00074

CAS Registry Number
214745-43-3